American Association for Cancer Research Press Conference Highlights Combination Potential of Two Cyclacel Pharmaceuticals, Inc. Drugs
Published: Apr 08, 2013
WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that the American Association of Cancer Research (AACR) highlighted data at a press conference in Washington, D.C. from a clinical trial evaluating a novel combination regimen of two of the Company's orally available, experimental drugs, sapacitabine and seliciclib. The trial enrolled patients with an incurable form of cancer associated with BRCA defects in the patients' genome. The press conference was held yesterday on the occasion of the American Association of Cancer Research (AACR) Annual Meeting 2013 which opened here this weekend.